Clearmind Medicine, Inc.(CMND)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CMND Clearmind Medicine, Inc.

盘前交易 12-19 08:17:28 EST

2.61

-0.19

-6.79%

盘前2.62

+0.01+0.38%

08:14 EST

最高2.84	最低2.40	成交量9.24万
今开2.70	昨收2.80	日振幅15.71%
总市值391.45万	流通市值325.85万	总股本149.98万
成交额24.79万	换手率7.40%	流通股本124.85万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CMND","market":"US","secType":"STK","nameCN":"Clearmind Medicine, Inc.","latestPrice":2.61,"timestamp":1766091600000,"preClose":2.8,"halted":0,"volume":92419,"hourTrading":{"tag":"盘前","latestPrice":2.62,"preClose":2.61,"latestTime":"08:14 EST","volume":3064,"amount":7884.7983264,"timestamp":1766150082066},"delay":0,"floatShares":1248466,"shares":1499796,"eps":-34.23868,"marketStatus":"盘前交易","change":-0.19,"latestTime":"12-19 08:17:28 EST","open":2.7,"high":2.8399,"low":2.4001,"amount":247862.4623913,"amplitude":0.157071,"askPrice":2.67,"askSize":1150,"bidPrice":2.55,"bidSize":984,"shortable":0,"etf":0,"ttmEps":-34.23868,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766154600000},"marketStatusCode":1,"adr":0,"listingDate":1668142800000,"exchange":"NASDAQ","adjPreClose":2.61,"preHourTrading":{"tag":"盘前","latestPrice":2.62,"preClose":2.61,"latestTime":"08:14 EST","volume":3064,"amount":7884.7983264,"timestamp":1766150082066},"postHourTrading":{"tag":"盘后","latestPrice":2.64,"preClose":2.61,"latestTime":"19:56 EST","volume":1616,"amount":4229.4598,"timestamp":1766105777148},"volumeRatio":0.1712099235017606},"requestUrl":"/m/hq/s/CMND/wiki","defaultTab":"wiki","newsList":[{"id":"1149510646","title":"Clearmind Medicine成功完成FDA批准的Cmnd-100 I/Ia试验第二组入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1149510646","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149510646?lang=zh_cn&edition=full","pubTime":"2025-12-16 21:46","pubTimestamp":1765892781,"startTime":"0","endTime":"0","summary":"Clearmind Medicine成功完成FDA批准的Cmnd-100 I/Ia试验第二组入组。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"1158559065","title":"Clearmind Medicine成功恢复符合纳斯达克最低股东权益要求","url":"https://stock-news.laohu8.com/highlight/detail?id=1158559065","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158559065?lang=zh_cn&edition=full","pubTime":"2025-12-12 19:32","pubTimestamp":1765539130,"startTime":"0","endTime":"0","summary":"Clearmind Medicine成功恢复符合纳斯达克最低股东权益要求","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"1186315731","title":"Clearmind Medicine在哈达萨医疗中心推进Cmnd-100进入剂量阶段，正在进行的酒精使用障碍I/Ia期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1186315731","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186315731?lang=zh_cn&edition=full","pubTime":"2025-12-02 20:58","pubTimestamp":1764680288,"startTime":"0","endTime":"0","summary":"Clearmind Medicine在哈达萨医疗中心推进Cmnd-100进入剂量阶段，正在进行的酒精使用障碍I/Ia期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"1183451380","title":"Clearmind Medicine在酗酒治疗上大步向前：积极的队列数据、全面的DSMB批准，以及新的优秀地点加入临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1183451380","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183451380?lang=zh_cn&edition=full","pubTime":"2025-12-01 21:57","pubTimestamp":1764597438,"startTime":"0","endTime":"0","summary":"Clearmind Medicine在酗酒治疗上大步向前：积极的队列数据、全面的DSMB批准，以及新的优秀地点加入临床试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"1123752604","title":"Clearmind Medicine在特拉维夫Sourasky医疗中心启动患者招募，新增一期酒精使用障碍临床试验地点","url":"https://stock-news.laohu8.com/highlight/detail?id=1123752604","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123752604?lang=zh_cn&edition=full","pubTime":"2025-11-25 20:21","pubTimestamp":1764073285,"startTime":"0","endTime":"0","summary":"Clearmind Medicine在特拉维夫Sourasky医疗中心启动患者招募，新增一期酒精使用障碍临床试验地点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"1125855202","title":"Clearmind Medicine的数据显示，数据与安全监测委员会一致批准继续进行Cmnd-100的I/Ia期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1125855202","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125855202?lang=zh_cn&edition=full","pubTime":"2025-11-24 21:52","pubTimestamp":1763992332,"startTime":"0","endTime":"0","summary":"Clearmind Medicine的数据显示，数据与安全监测委员会一致批准继续进行Cmnd-100的I/Ia期临床试验，这是基于对 interim安全性审查的积极结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"1103700947","title":"Clearmind Medicine通过激活全球第五个顶级医疗中心加速FDA批准的酒精使用障碍临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1103700947","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103700947?lang=zh_cn&edition=full","pubTime":"2025-11-20 19:02","pubTimestamp":1763636541,"startTime":"0","endTime":"0","summary":"Clearmind Medicine通过激活全球第五个顶级医疗中心加速FDA批准的酒精使用障碍临床试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"1162598345","title":"Clearmind Medicine签署证券购买协议，以注册直接发行方式购买和销售10,925,000股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1162598345","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162598345?lang=zh_cn&edition=full","pubTime":"2025-11-19 19:12","pubTimestamp":1763550736,"startTime":"0","endTime":"0","summary":"Clearmind Medicine签署证券购买协议，以注册直接发行方式购买和销售10,925,000股普通股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"1154008418","title":"Clearmind Medicine公布FDA批准的I/Iia期临床试验首个阶段积极的顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1154008418","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154008418?lang=zh_cn&edition=full","pubTime":"2025-11-18 21:58","pubTimestamp":1763474337,"startTime":"0","endTime":"0","summary":"Clearmind Medicine公布FDA批准的I/Iia期临床试验首个阶段积极的顶线结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"1187794529","title":"Clearmind Medicine获得最终批准，扩展其在Hadassah医疗中心针对酒精使用障碍的FDA监管I/IIa期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1187794529","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187794529?lang=zh_cn&edition=full","pubTime":"2025-11-13 21:55","pubTimestamp":1763042130,"startTime":"0","endTime":"0","summary":"Clearmind Medicine获得最终批准，扩展其在Hadassah医疗中心针对酒精使用障碍的FDA监管I/IIa期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"1103301152","title":"Clearmind Medicine 在其 FDA 批准的 I/Ia 期临床试验中成功完成首个队列治疗，针对酒精使用障碍","url":"https://stock-news.laohu8.com/highlight/detail?id=1103301152","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103301152?lang=zh_cn&edition=full","pubTime":"2025-11-10 21:07","pubTimestamp":1762780037,"startTime":"0","endTime":"0","summary":"Clearmind Medicine 在其 FDA 批准的 I/Ia 期临床试验中成功完成首个队列治疗，针对酒精使用障碍","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"1173884562","title":"Clearmind Medicine, Inc.在抑郁症治疗领域通过新申请的韩国专利拓展全球知识产权保护","url":"https://stock-news.laohu8.com/highlight/detail?id=1173884562","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173884562?lang=zh_cn&edition=full","pubTime":"2025-11-05 19:57","pubTimestamp":1762343848,"startTime":"0","endTime":"0","summary":"Clearmind Medicine, Inc.在抑郁症治疗领域通过新申请的韩国专利拓展全球知识产权保护。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"1151863712","title":"Clearmind Medicine完成FDA批准的I/Ia期临床试验中的首个队列治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1151863712","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151863712?lang=zh_cn&edition=full","pubTime":"2025-10-30 19:55","pubTimestamp":1761825322,"startTime":"0","endTime":"0","summary":"Clearmind Medicine完成FDA批准的I/Ia期临床试验中的首个队列治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"1191774743","title":"Clearmind Medicine完成FDA批准的I/Ia期临床试验首批患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1191774743","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191774743?lang=zh_cn&edition=full","pubTime":"2025-10-21 19:25","pubTimestamp":1761045922,"startTime":"0","endTime":"0","summary":"Clearmind Medicine完成FDA批准的I/Ia期临床试验首批患者招募。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"1192639784","title":"SciSparc与Clearmind合作推动美国专利申请公布，聚焦暴饮暴食行为障碍","url":"https://stock-news.laohu8.com/highlight/detail?id=1192639784","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192639784?lang=zh_cn&edition=full","pubTime":"2025-10-20 19:42","pubTimestamp":1760960529,"startTime":"0","endTime":"0","summary":"SciSparc与Clearmind合作推动美国专利申请的公布，专注于暴饮暴食行为障碍的治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4139","BK4007","SPRC"],"gpt_icon":0},{"id":"1107927877","title":"Clearmind Medicine, Inc.获得1000万美元证券购买协议以探索战略机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=1107927877","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107927877?lang=zh_cn&edition=full","pubTime":"2025-09-19 20:20","pubTimestamp":1758284418,"startTime":"0","endTime":"0","summary":"Clearmind Medicine, Inc.获得1000万美元证券购买协议以探索战略机遇","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2545479542","title":"Clearmind Medicine(CMND.US)：2025年Q2财报实现营收0美元，前值为0美元；每股收益为-0.16美元，前值为-0.28美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2545479542","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545479542?lang=zh_cn&edition=full","pubTime":"2025-06-24 12:14","pubTimestamp":1750738447,"startTime":"0","endTime":"0","summary":"Clearmind Medicine(CMND.US)：2025年Q2财报实现营收0美元，前值为0美元；每股收益为-0.16美元，前值为-0.28美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/24121451259093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CMND"],"gpt_icon":0},{"id":"2512701480","title":"Clearmind Medicine Inc.盘中异动 股价大跌5.11%报1.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512701480","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512701480?lang=zh_cn&edition=full","pubTime":"2025-02-20 01:51","pubTimestamp":1739987475,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日01时51分，Clearmind Medicine Inc.股票出现波动，股价快速下跌5.11%。截至发稿，该股报1.30美元/股，成交量5.1213万股，换手率1.09%，振幅4.37%。Clearmind Medicine Inc.股票所在的生物技术行业中，整体涨幅为0.53%。Clearmind Medicine Inc.公司简介：Clearmind Medicine Inc是一家迷幻药生物技术公司，专注于发现和开发新型迷幻药衍生疗法，以解决广泛存在且服务不足的健康问题，包括酒精使用障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220015115a24c1f55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220015115a24c1f55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CMNDF","CMNDD","BK4007","CMND"],"gpt_icon":0},{"id":"2510862369","title":"Clearmind Medicine Inc.盘中异动 早盘股价大涨5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510862369","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510862369?lang=zh_cn&edition=full","pubTime":"2025-02-11 00:18","pubTimestamp":1739204300,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日00时18分，Clearmind Medicine Inc.股票出现波动，股价大幅拉升5.15%。截至发稿，该股报1.43美元/股，成交量1.8911万股，换手率0.40%，振幅4.78%。Clearmind Medicine Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Clearmind Medicine Inc.公司简介：Clearmind Medicine Inc是一家迷幻药生物技术公司，专注于发现和开发新型迷幻药衍生疗法，以解决广泛存在且服务不足的健康问题，包括酒精使用障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211001821a240b8d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211001821a240b8d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CMND","CMNDF","BK4007","CMNDD"],"gpt_icon":0},{"id":"2509308728","title":"Clearmind Medicine Inc.盘中异动 股价大跌5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509308728","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509308728?lang=zh_cn&edition=full","pubTime":"2025-02-07 23:45","pubTimestamp":1738943100,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日23时45分，Clearmind Medicine Inc.股票出现波动，股价快速下挫5.59%。Clearmind Medicine Inc.股票所在的生物技术行业中，整体跌幅为0.08%。Clearmind Medicine Inc.公司简介：Clearmind Medicine Inc是一家迷幻药生物技术公司，专注于发现和开发新型迷幻药衍生疗法，以解决广泛存在且服务不足的健康问题，包括酒精使用障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207234501abc63b77&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207234501abc63b77&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CMNDF","CMNDD","BK4007","CMND"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.clearmindmedicine.com","stockEarnings":[{"period":"1week","weight":-0.09},{"period":"1month","weight":-0.6985},{"period":"3month","weight":-0.9452},{"period":"6month","weight":-0.9264},{"period":"1year","weight":-0.9433},{"period":"ytd","weight":-0.9527}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0192},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.1538},{"period":"ytd","weight":0.1542}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Clearmind Medicine Inc.于2017年7月18日在不列颠哥伦比亚省注册成立。他们是一家接近1期临床试验的临床前制药公司，开发新型迷幻药物以解决广泛存在但服务不足的健康问题。他们的目标是为AUD开发和提供一种新型治疗方法，包括暴饮暴食症，在这些疾病中存在大量未满足的需求和缺乏创新。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.120452},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.046234},{"month":3,"riseRate":0,"avgChangeRate":-0.347646},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.169588},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.01702},{"month":6,"riseRate":0.333333,"avgChangeRate":0.080414},{"month":7,"riseRate":0.333333,"avgChangeRate":0.008507},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.088917},{"month":9,"riseRate":0,"avgChangeRate":-0.22938},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.107561},{"month":11,"riseRate":0,"avgChangeRate":-0.304445},{"month":12,"riseRate":0.25,"avgChangeRate":-0.224253}],"exchange":"NASDAQ","name":"Clearmind Medicine, Inc.","nameEN":"Clearmind Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Clearmind Medicine, Inc.(CMND)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Clearmind Medicine, Inc.(CMND)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Clearmind Medicine, Inc.,CMND,Clearmind Medicine, Inc.股票,Clearmind Medicine, Inc.股票老虎,Clearmind Medicine, Inc.股票老虎国际,Clearmind Medicine, Inc.行情,Clearmind Medicine, Inc.股票行情,Clearmind Medicine, Inc.股价,Clearmind Medicine, Inc.股市,Clearmind Medicine, Inc.股票价格,Clearmind Medicine, Inc.股票交易,Clearmind Medicine, Inc.股票购买,Clearmind Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Clearmind Medicine, Inc.(CMND)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Clearmind Medicine, Inc.(CMND)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}